OBJECTIVE: The study was done to evaluate the efficacy of ormeloxifene in medical management of dysfunctional uetrine bleeding. METHODS: Thirty women in reproductive age group who have completed child bearing, attending the outpatient gynaecology department with complaint of heavy menstrual flow were recruited for the study over a period of one year. Ormeloxifene (60 mg) was given orally twice a week for first 12 weeks and then once a week for up to next 12 weeks. Menstrual blood loss measurement was done using pictorial blood loss assessment chart (PBAC), blood haemoglobin (gm/ dl) levels and endometrial thickness was the main measurements to evaluate the efficacy of therapy. The data obtained was analyzed using the mean and p values of less than 0.05 were accepted as indicating statistical significance. RESULTS: There was a significant reduction in PBAC score from pre-treatment and post-treatment with ormeloxifene (p˂0.001).There was also significant reduction in the endometrial thickness after treatment (p˂0.001).The difference in mean haemoglobin concentration of 2.02 gm/dl between pre-treatment and post-treatment.no major adverse effects were seen in the study. CONCLUSION: The results in this study showed that ormeloxifene, a non-hormonal, non- steriodal agent provides effective and favourable medical management with least side effects, suitable for the treatment of dysfunctional uterine bleeding